Clozapine haematological monitoring for neutropenia: a global perspective

E Oloyede, G Blackman, E Whiskey… - Epidemiology and …, 2022 - cambridge.org
AimsClozapine is licensed for treatment-resistant psychosis and remains underutilised. This
may berelated to the stringent haematological monitoring requirements that are mandatory …

Risks and benefits of clozapine and lithium co-prescribing: a systematic review and expert recommendations

H Verdoux, C Quiles, J de Leon - Schizophrenia research, 2023 - Elsevier
Objectives To identify the risks and benefits of clozapine‑lithium co-prescription. Methods
Articles published in English or French were identified with a MEDLINE, Web of Sciences …

A population pharmacokinetic model to guide clozapine dose selection, based on age, sex, ethnicity, body weight and smoking status

S Reeves, J Bertrand, SJ Obee… - British Journal of …, 2024 - Wiley Online Library
Aims Guidance on clozapine dosing in treatment‐resistant schizophrenia is based largely
on data from White young adult males. This study aimed to investigate the pharmacokinetic …

[HTML][HTML] Slower clozapine titration than the official Japanese protocol led to fewer inflammatory adverse effects: a retrospective chart review of seven hospitals

Y Kikuchi, H Komatsu, Y Otsuka, F Ito, N Kanahara… - Schizophrenia …, 2024 - Elsevier
Background Higher frequencies of inflammatory adverse effects of clozapine have been
reported in Japan. As the international titration protocol for Asians has set slower dose …

Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring: Can the regulations be relaxed?

PFJ Schulte, SRT Veerman, B Bakker… - Schizophrenia …, 2024 - Elsevier
After the introduction of clozapine eight Finnish patients died after develo**
agranulocytosis. Clozapine was withdrawn from the market and only reintroduced with strict …

Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia

M Qubad, RA Bittner - Therapeutic advances in …, 2023 - journals.sagepub.com
Despite its enduring relevance as the single most effective and important evidence-based
treatment for schizophrenia, underutilization of clozapine remains considerable. To a …

Clinical impact of reducing the frequency of clozapine monitoring: controlled mirror-image cohort study

E Oloyede, O Dzahini, Z Abolou, S Gee… - The British Journal of …, 2023 - cambridge.org
BackgroundTo minimise infection during COVID-19, the clozapine haematological
monitoring interval was extended from 4-weekly to 12-weekly intervals in South London and …

The lived experience of clozapine discontinuation in patients and carers following suspected clozapine-induced neutropenia

E Oloyede, D Dunnett, D Taylor, I Clark, JH MacCabe… - BMC psychiatry, 2023 - Springer
Background Clozapine is the treatment of choice in refractory psychosis. In most countries,
clozapine must be stopped indefinitely if white blood cells fall below a defined threshold …

International variation in clozapine hematologic monitoring—a call for action

E Oloyede, D Taylor, J MacCabe - JAMA psychiatry, 2023 - jamanetwork.com
Clozapine Clozapine was first synthesized in the 1950s but remains the only licensed
medication for treatmentresistant psychosis. 1 Treatment-resistant psychosis, defined as the …

Understanding clozapine-related blood dyscrasias. Developments, genetics, ethnicity and disparity: it's a CIN

E Silva, S Legge, C Casetta, E Whiskey, E Oloyede… - BJPsych …, 2024 - cambridge.org
Clozapine remains the gold standard intervention for treatment-resistant schizophrenia;
however, it remains underused, especially for some minority groups. A significant …